Innocan Pharma Secures $1.4M Via Private Placement

Innocan Pharma Corporation INNPF INNO IP has closed a non-brokered private placement offering of 8.4 million units of Innocan at a price of CA$0.23 per unit for aggregate gross proceeds of CA$1.9 million ($1.4 million).

Each unit consists of:

• One common share in the capital of the company;

• One-half of one class A common share purchase warrant;

• One-half of one class B common share purchase warrant.

Each class A warrant will entitle the holder thereof to purchase one common share at a price of CA$0.29 for a period of three years from the date of issuance. Each class B warrant will entitle the holder thereof to purchase one common share at a price of CA$0.40 for a period of five years from the date of issuance.

Innocan intends to use the proceeds of the offering for working capital and general corporate purposes.

The securities issued in connection with the offering will be subject to a four-month hold period, in accordance with applicable Canadian securities laws.

Benzinga Cannabis Capital Conference

The Benzinga Cannabis Capital Conference, the place where deals get done, is returning to Chicago this Sept 27-28 for its 17th edition. Get your tickets today before prices increase and secure a spot at the epicenter of cannabis investment and branding.

Photo by Mackenzie Marco on Unsplash

Related News

Innocan Pharma To Secure Up To $3M Via Private Placement Of Units At A 9% Prime Above Share Price

Innocan Pharma Q1 Revenue Grows 500% YoY, Here Is What You Need To Know

Innocan Pharma FY22 Revenue Grows 1205% To $2.6M, Here Is What You Need To Know